These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9781436)

  • 1. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.
    Noguchi K; Harada M; Masuda M; Takeda M; Kinoshita Y; Fukushima S; Miyai K; Fukuoka H; Hosaka M
    Int J Urol; 1998 Sep; 5(5):466-70. PubMed ID: 9781436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
    Noguchi K; Takeda M; Hosaka M; Kubota Y
    Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.
    Kurita Y; Masuda H; Suzuki K; Fujita K; Kawabe K
    Br J Urol; 1997 Jul; 80(1):78-83. PubMed ID: 9240185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement].
    Tsuji Y; Ariyoshi A; Nakamura H; Michinaga S; Tomita Y; Ohmori A; Tahara H; Yamashita Y; Fujisawa Y; Kajiwara I
    Hinyokika Kiyo; 1992 Aug; 38(8):961-6. PubMed ID: 1384295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of allylestrenol on prostatic hypertrophy].
    Kohri K; Kurita T; Iguchi M; Kataoka K
    Hinyokika Kiyo; 1986 Mar; 32(3):486-92. PubMed ID: 2425611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of allylestrenol (Org AL-25) on patients with prostatic hypertrophy--transrectal ultrasonography and urodynamic examination].
    Ohyama M; Tanifuji T; Haraguchi C; Fujii N; Higaki Y; Yoshida H; Imamura K
    Hinyokika Kiyo; 1986 Apr; 32(4):649-59. PubMed ID: 2426933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effect of allylestrenol on benign prostatic hypertrophy].
    Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A
    Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy].
    Fukuoka H; Ishibashi Y; Shiba T; Tuchiya F; Sakanishi S
    Hinyokika Kiyo; 1993 Jul; 39(7):679-83. PubMed ID: 7689782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol].
    Yamanaka H; Kosaku N; Makino T; Shida K
    Hinyokika Kiyo; 1983 Sep; 29(9):1133-45. PubMed ID: 6203385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
    Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
    Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
    Moon KT; Yoo TK; Kwon SY; Ha JY; Byun SS; Kim JH; Chung JI; Kim TH; Moon HS; Kim SJ; Lee KS
    BJU Int; 2018 Aug; 122(2):283-292. PubMed ID: 29633507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
    J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method].
    Shida K; Koyanagi T; Kawakura K; Nishida T; Kumamoto Y; Orikasa S; Sato S; Takeda M; Yamanaka H; Shimazaki J
    Hinyokika Kiyo; 1986 Apr; 32(4):625-48. PubMed ID: 2426932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
    Umeda K
    Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.